Senior Manager, Real-World Data and Analytics (HEOR)-1
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Senior Manager, Real-World Data and Analytics (RWDnA) will support the generation of real-world evidence (RWE) in oncology by delivering data-driven insights through the analysis of real-world data (RWD). The individual will contribute to query/protocol/statistical analysis (SAP) development and execute analyses of RWD to support the generation of RWE to address research questions. The successful candidate will conduct hands-on programming on internal RWD assets, support publication activities, and participate in vendor management.
Job description
Discover your role:
- Contribute to the development of RWE queries, protocols, and statistical analysis plans (SAPs) within oncology
- Translate analytic findings into clear insights and communicate them directly to project teams
- Support end-to-end RWE query and study delivery, including hands-on programming and quality control of analytic code
- Evaluate and identify appropriate real-world data sources to address specific research questions
- Contribute to scientific communications, including abstracts, posters, manuscripts, and internal presentations
- Support senior team members in coordinating activities with external analytics vendors and research partners
This role requires:
- Doctoral degree in a quantitative field focused on the application of data science to healthcare data with 2+ years of hands-on programming experience; or a Master's degree in a related field with 4+ years of hands-on programming experience
- Hands-on experience with real-world data sources such as large-scale administrative claims data (e.g., Optum, Medicare, Komodo claims) and electronic health records (EHRs)
- Experience in oncology research and with oncology-specific real-world data (e.g., Flatiron, ConcertAI)
- Advanced programming capabilities using SAS and R
- Proficiency in statistical methodologies including survival analysis, propensity score methods, and generalized linear models.
- Experience with machine learning approaches applied to real-world data
- Excellent written and verbal communication skills
Requirements
- Doctoral degree in a quantitative field focused on the application of data science to healthcare data with 2+ years of hands-on programming experience; or a Master's degree in a related field with 4+ years of hands-on programming experience
- Hands-on experience with real-world data sources such as large-scale administrative claims data (e.g., Optum, Medicare, Komodo claims) and electronic health records (EHRs)
- Experience in oncology research and with oncology-specific real-world data (e.g., Flatiron, ConcertAI)
- Advanced programming capabilities using SAS and R
- Proficiency in statistical methodologies including survival analysis, propensity score methods, and generalized linear models.
- Experience with machine learning approaches applied to real-world data
- Excellent written and verbal communication skills
Benefits
- Annual bonuses
- Incentive plans
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Medical insurance
- Dental insurance
- Vision insurance
- Life and disability insurance
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.